181 related articles for article (PubMed ID: 10745083)
1. Evaluation of inhibition of the carbenicillin-hydrolyzing beta-lactamase PSE-4 by the clinically used mechanism-based inhibitors.
Therrien C; Kotra LP; Sanschagrin F; Mobashery S; Levesque RC
FEBS Lett; 2000 Mar; 470(3):285-92. PubMed ID: 10745083
[TBL] [Abstract][Full Text] [Related]
2. Inhibitor resistance in the KPC-2 beta-lactamase, a preeminent property of this class A beta-lactamase.
Papp-Wallace KM; Bethel CR; Distler AM; Kasuboski C; Taracila M; Bonomo RA
Antimicrob Agents Chemother; 2010 Feb; 54(2):890-7. PubMed ID: 20008772
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a PSE-4 mutant with different properties in relation to penicillanic acid sulfones: importance of residues 216 to 218 in class A beta-lactamases.
Sabbagh Y; Thériault E; Sanschagrin F; Voyer N; Palzkill T; Levesque RC
Antimicrob Agents Chemother; 1998 Sep; 42(9):2319-25. PubMed ID: 9736556
[TBL] [Abstract][Full Text] [Related]
4. Different intermediate populations formed by tazobactam, sulbactam, and clavulanate reacting with SHV-1 beta-lactamases: Raman crystallographic evidence.
Kalp M; Totir MA; Buynak JD; Carey PR
J Am Chem Soc; 2009 Feb; 131(6):2338-47. PubMed ID: 19161282
[TBL] [Abstract][Full Text] [Related]
5. Following the reactions of mechanism-based inhibitors with beta-lactamase by Raman crystallography.
Helfand MS; Totir MA; Carey MP; Hujer AM; Bonomo RA; Carey PR
Biochemistry; 2003 Nov; 42(46):13386-92. PubMed ID: 14621983
[TBL] [Abstract][Full Text] [Related]
6. Kinetic analysis of an inhibitor-resistant variant of the OHIO-1 beta-lactamase, an SHV-family class A enzyme.
Lin S; Thomas M; Shlaes DM; Rudin SD; Knox JR; Anderson V; Bonomo RA
Biochem J; 1998 Jul; 333 ( Pt 2)(Pt 2):395-400. PubMed ID: 9735103
[TBL] [Abstract][Full Text] [Related]
7. Clinical inhibitor-resistant mutants of the beta-lactamase TEM-1 at amino-acid position 69. Kinetic analysis and molecular modelling.
Chaibi EB; Péduzzi J; Farzaneh S; Barthélémy M; Sirot D; Labia R
Biochim Biophys Acta; 1998 Jan; 1382(1):38-46. PubMed ID: 9507060
[TBL] [Abstract][Full Text] [Related]
8. Structure-function analysis of alpha-helix H4 using PSE-4 as a model enzyme representative of class A beta-lactamases.
Savoie A; Sanschagrin F; Palzkill T; Voyer N; Levesque RC
Protein Eng; 2000 Apr; 13(4):267-74. PubMed ID: 10810158
[TBL] [Abstract][Full Text] [Related]
9. Tazobactam is a potent inactivator of selected inhibitor-resistant class A beta-lactamases.
Bonomo RA; Rudin SA; Shlaes DM
FEMS Microbiol Lett; 1997 Mar; 148(1):59-62. PubMed ID: 9066111
[TBL] [Abstract][Full Text] [Related]
10. Substrate selectivity and a novel role in inhibitor discrimination by residue 237 in the KPC-2 beta-lactamase.
Papp-Wallace KM; Taracila M; Hornick JM; Hujer AM; Hujer KM; Distler AM; Endimiani A; Bonomo RA
Antimicrob Agents Chemother; 2010 Jul; 54(7):2867-77. PubMed ID: 20421396
[TBL] [Abstract][Full Text] [Related]
11. Raman crystallographic studies of the intermediates formed by Ser130Gly SHV, a beta-lactamase that confers resistance to clinical inhibitors.
Helfand MS; Taracila MA; Totir MA; Bonomo RA; Buynak JD; van den Akker F; Carey PR
Biochemistry; 2007 Jul; 46(29):8689-99. PubMed ID: 17595114
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of a class A and a class C β-lactamase by 6β-(hydroxymethyl)penicillanic acid sulfone.
Papp-Wallace KM; Bethel CR; Gootz TD; Shang W; Stroh J; Lau W; McLeod D; Price L; Marfat A; Distler A; Drawz SM; Chen H; Harry E; Nottingham M; Carey PR; Buynak JD; Bonomo RA
Biochem Pharmacol; 2012 Feb; 83(4):462-71. PubMed ID: 22155308
[TBL] [Abstract][Full Text] [Related]
13. Exploring the inhibition of CTX-M-9 by beta-lactamase inhibitors and carbapenems.
Bethel CR; Taracila M; Shyr T; Thomson JM; Distler AM; Hujer KM; Hujer AM; Endimiani A; Papp-Wallace K; Bonnet R; Bonomo RA
Antimicrob Agents Chemother; 2011 Jul; 55(7):3465-75. PubMed ID: 21555770
[TBL] [Abstract][Full Text] [Related]
14. Comparative in-vitro activities of GD-40 and other beta-lactamase inhibitors against TEM-1 and SHV-2 beta-lactamases.
Danelon G; Mascaretti O; Radice M; Power P; Calcagno ML; Mata EG; Gutkind G
J Antimicrob Chemother; 1998 Feb; 41(2):313-5. PubMed ID: 9533481
[No Abstract] [Full Text] [Related]
15. Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130.
Helfand MS; Bethel CR; Hujer AM; Hujer KM; Anderson VE; Bonomo RA
J Biol Chem; 2003 Dec; 278(52):52724-9. PubMed ID: 14534312
[TBL] [Abstract][Full Text] [Related]
16. Beta-lactamase inhibitors: relation between kinetic data and in-vitro synergism studies.
Cullmann W
Zentralbl Bakteriol; 1991 Oct; 275(4):500-3. PubMed ID: 1661596
[TBL] [Abstract][Full Text] [Related]
17. Novel insights into the mode of inhibition of class A SHV-1 beta-lactamases revealed by boronic acid transition state inhibitors.
Ke W; Sampson JM; Ori C; Prati F; Drawz SM; Bethel CR; Bonomo RA; van den Akker F
Antimicrob Agents Chemother; 2011 Jan; 55(1):174-83. PubMed ID: 21041505
[TBL] [Abstract][Full Text] [Related]
18. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam.
Muratani T; Yokota E; Nakane T; Inoue E; Mitsuhashi S
J Antimicrob Chemother; 1993 Sep; 32(3):421-9. PubMed ID: 8262864
[TBL] [Abstract][Full Text] [Related]
19. A structure-based analysis of the inhibition of class A beta-lactamases by sulbactam.
Imtiaz U; Billings EM; Knox JR; Mobashery S
Biochemistry; 1994 May; 33(19):5728-38. PubMed ID: 8180199
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a beta-lactamase produced by Pseudomonas paucimobilis.
Corkill JE; Hart CA; McLennan AG; Aspinall S
J Gen Microbiol; 1991 Jun; 137(6):1425-9. PubMed ID: 1655952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
